Author

M. A. Lyons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. A. Bauman· 2 shared G. T. Robertson· 2 shared M. E. Ramey· 2 shared A. Amalric· 1 shared A. J. Lenaerts· 1 shared A. Obregon-Henao· 1 shared A. R. Cole· 1 shared A. Uboveja· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. A. Bauman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis

A. A. Bauman, J. P. Sarathy, F. Kaya, L. M. Massoudi, M. S. Scherman, C. Hastings, J. Liu, M. Xie, E. J. Brooks, M. E. Ramey, I. L. Jones, N. D. Benedict, M. R. Maclaughlin, J. A. Miller-Dawson, S. L. Waidyarachchi, , G. T. Robertson

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

bioRxiv · May 13, 2024Microbiology

Use of Multiple Pharmacodynamic Measures to Deconstruct the Nix-TB Regimen in a Short-Course Murine Model of Tuberculosis

M. A. Lyons, A. Obregon-Henao, M. E. Ramey, A. A. Bauman, S. Pauly, K. Rossmassler, J. Reid, B. Karger, N. D. Walter, G. T. Robertson

The paper evaluates the Nix-TB regimen in a murine TB model using pharmacodynamic markers to assess drug contributions and interactions.

bioRxiv · Nov 8, 2023Pharmacology & Toxicology

De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression

N. K. Tangudu, R. Buj, H. Wang, J. Wang, A. R. Cole, A. Uboveja, R. Fang, A. Amalric, P. Sajjakulnukit, M. A. Lyons, K. Cooper, N. W. Hempel, N. W. Snyder, C. A. Lyssiotis, U. R. Chandran, K. M. Aird

This study identifies de novo purine metabolism as a vulnerability in cancers with low p16 expression, showing sensitivity to anti-folate drugs like methotrexate.

bioRxiv · Jul 15, 2023Cancer Biology